Study summary

Nipocalimab lowered harmful antibodies and improved daily function

Vivacity-MG3 trial · 196 people, phase 3 · Published February 2025, Lancet Neurology; FDA approved 2025 (Imaavy)

-4.70point MG-ADL change with nipocalimab, vs -3.25

What was tested

Nipocalimab, an FcRn blocker that clears IgG antibodies, against placebo in generalized myasthenia gravis not controlled by standard care.

What they found

MG-ADL improved 4.70 vs 3.25 points over weeks 22 to 24.
Serious side effects: 9% vs 14% with placebo.

What it means

Joins efgartigimod and rozanolixizumab as FcRn options.

Lancet Neurol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.